Journal article
Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice
JA Westwood, TCU Potdevin Hunnam, HJ Pegram, RJ Hicks, PK Darcy, MH Kershaw
Plos One | Published : 2014
Abstract
We have found previously that the tumor cell lines, Renca (a renal cancer) and MC38 (a colon tumor) which had been injected subcutaneously in mice, could be successfully treated with a combination therapy of an oligodeoxynucleotide (CpG1826) (injected intratumorally) and anti-CD137 antibody (injected intraperitoneally). Thus the combination treatment was expected to initiate a "danger" signal via TLR9 on immune cells, and the anti-CD137 was expected to further activate T cells. In the present study, we found that several other tumor types injected subcutaneously could also be successfully treated with this combination therapy. In addition, we wished to determine if the treatment could work a..
View full abstractGrants
Funding Acknowledgements
This work was supported by funding from the Bob Parker Memorial Fund, The Peter MacCallum Cancer Centre Foundation, Cancer Council Victoria, and the National Health and Medical Research Council of Australia (NHMRC). MHK and PKD were supported by Senior Research Fellowships from the NHMRC. MK, PD, and JW were funded by NHMRC, Grant #1013668. URL: www.nhmrc.gov.au/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.